Exclusive Free Symposium on Federal Initiatives Toward Single IRB Review
January 30th, 2017
Schulman IRB Connections Presents: Emerging Issues in Research – Federal Initiatives Toward Single IRB Review
Join industry colleagues February 15 for an interactive presentation and discussion of emerging issues in research.
*This event has concluded. Thanks to everyone who joined the conversation in Boston!*
Recent federal initiatives make it clear that the US government favors single IRB review in multisite clinical trials. The NIH sIRB policy, 21st Century Cures Act, the final revised Common Rule and other requirements pose unique challenges as research organizations plan how they will maintain compliance with current and evolving regulations.
To help you navigate the important decisions surrounding single IRB review, Schulman IRB is hosting a panel discussion which will examine different perspectives on this emerging issue from a variety of stakeholders. The dialogue will be facilitated by Michele Russell-Einhorn, Schulman’s VP of Human Research Protection Services and Institutional Official (formerly Senior Director of Dana-Farber Cancer Institute, Office for Human Research Studies).
*Following our feature discussion, attendees are welcome to stay and join us
for a mini-workshop on eConsent, another current hot topic in research.
When: Wednesday, February 15, 7:00-11:00am
Where: The Joseph B Martin Conference Center at Harvard Medical School, Boston, MA
Who Should Attend: Investigators, Research Administrators, IRB Members, Clinical Research Managers and Directors, Project Managers, Regulatory Affairs Professionals and others involved in the planning and management of clinical research involving human participants
Cost to Attend: Free
- Michele Russell-Einhorn, JD, Vice President of Human Research Protection Services and Institutional Official at Schulman IRB
- Deborah Jakubowski Russ, MS, Manager, Clinical Operations at PAREXEL International
- Richard Penson, MD, Associate Professor, Medicine at Harvard Medical School; Clinical Director Medical Gynecologic Oncology, Medicine at Massachusetts General Hospital; and IRB Chair at Dana-Farber/Harvard Cancer Center
- Kathy Carbone, RN, MSN, Director, GCO Vendor Management, Global Clinical Operations at Biogen
Schulman IRB is not affiliated with Harvard University, nor is Schulman IRB a Harvard University program or activity.